2019
DOI: 10.1002/cam4.2492
|View full text |Cite
|
Sign up to set email alerts
|

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy

Abstract: The overall survival rates for lung cancer remain unsatisfactorily low, even for patients with biomarkers for which target therapies or immunotherapies are recommended. Better identification of at‐risk patients is needed to achieve more effective personalized treatment. Here, we derived a risk‐stratifying gene signature consisting of five genes that had the greatest differential expression by stage from lung adenocarcinoma (LUAD) transcriptomes. The new gene signature enabled survival prognosis for multiple LU… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 48 publications
0
6
0
Order By: Relevance
“…To compare its specificity and sensitivity with other well-known cancer biomarkers [ 21 ] and cancer-related lncRNAs [ 18 ], we calculated the ROC curves of the EGFR, TP53, and TP53 genes, as well as the oncogenic lncRNAs MALAT-1 and NEAT1, using TCGA-LUAD data. We obtained AUC values of 0.539, 0.703, 0.542, and 0.573, respectively, which are considerably lower than the AUC values obtained for DLG2-AS1 ( Figure 2 b).…”
Section: Resultsmentioning
confidence: 99%
“…To compare its specificity and sensitivity with other well-known cancer biomarkers [ 21 ] and cancer-related lncRNAs [ 18 ], we calculated the ROC curves of the EGFR, TP53, and TP53 genes, as well as the oncogenic lncRNAs MALAT-1 and NEAT1, using TCGA-LUAD data. We obtained AUC values of 0.539, 0.703, 0.542, and 0.573, respectively, which are considerably lower than the AUC values obtained for DLG2-AS1 ( Figure 2 b).…”
Section: Resultsmentioning
confidence: 99%
“…TP53 mutation is not only the most common genetic event in NSCLC but also reported to be associated with poor prognosis in cancers, especially non-small cell lung cancer ( Ozaki and Nakagawara, 2011 ). TP53 mutation could affect disease progression, tumor cell characteristics, and the therapeutic effect of different therapeutics ( Wu and Hwang, 2019 ). In addition, the more enrichment of KEAP1 mutations in TMEscore high tumors than TMEscore low may be one potential explanation for the distinct performance of ICI efficacy in LUAD.…”
Section: Discussionmentioning
confidence: 99%
“…Marinelli et al ( 26 ) confirmed that the efficacy of immunotherapy had notable interpatient heterogeneity in patients with LUAD. In addition, immune checkpoint inhibitors were of benefit to a great deal patients with LUAD, and a small mutation panel of coding sequences could predict the long-term outcome of immunotherapy ( 27 ). In the current study, 19 differentially expressed membrane proteins were found to be associated with immune processes, indicating that these cell membrane proteins may be potential immunotherapeutic targets.…”
Section: Discussionmentioning
confidence: 99%